MYIA
HAE icon

Mount Yale Investment Advisors’s Haemonetics HAE Stock Holding History

Mount Yale Investment Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+2,987
New +$192K ﹤0.01% 1106
2025
Q3 		– Sell
-863
Closed -$64.4K – 1060
2025
Q2 		$64.4K Buy
+863
New +$57.1K 0.01% 747
2018
Q2 		– Sell
-194
Closed -$14K – 970
2018
Q1 		$14K Buy
+194
New +$13.3K ﹤0.01% 820

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mount Yale Investment Advisors's HAE Position: Q2 2026 in Review

Mount Yale Investment Advisors opened a new position in Haemonetics (HAE) in Q2 2026: 2,987 shares worth $224K. The stake represents ﹤0.01% of the portfolio and ranks #1106 among its holdings. This is a return to the name: Mount Yale Investment Advisors previously reported a position in HAE as recently as Q2 2025.

Mount Yale Investment Advisors first reported a position in HAE in Q1 2018 and has held it in 3 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Mount Yale Investment Advisors held 2,987 shares of Haemonetics worth $224K as of Q2 2026.
  • Haemonetics was a new Mount Yale Investment Advisors position in Q2 2026.
  • Haemonetics made up ﹤0.01% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #1106 holding.
  • Mount Yale Investment Advisors first reported a position in Haemonetics in Q1 2018 and has held it in 3 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.